2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Newborn Screening, Omics Technologies, Pathology, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Surgical, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

6097 Genotyping of targeted hotspots and mRNA (GoTHaM) reveals clone-specific cytotoxic immune reprogramming in TET2-mutant CHIP

Joe Pelt, MSc, BSc, Elliot O Eton, BA2, Abigail G Thress3, Tamara Prieto4, John Zinno5, Jesus Sotelo6, Franco Izzo, PhD7, Hui Yang, MD, PhD8, Guillermo Garcia-Manero, MD9, Catherine Potenski10, Mandeep Singh11, Ivan Raimondi12, Dan Avi Landau, MD, PhD13
1 New York Genome Center, New York, NY, United States, Sandra and Edward Meyer Cancer Center, New York, NY, United States, Tri-Institutional MD-PhD Program, New York, NY, United States
2 New York Genome Center, New York, NY, United States, Sandra and Edward Meyer Cancer Center, New York, NY, United States, Tri-Institutional MD-PhD Program, New York, NY, United States
3 New York Genome Center, New York, NY, United States, Sandra and Edward Meyer Cancer Center, New York, NY, United States
4 New York Genome Center, New York, NY, United States, Sandra and Edward Meyer Cancer Center, New York, NY, United States
5 New York Genome Center, New York, NY, United States, Sandra and Edward Meyer Cancer Center, New York, NY, United States
6 Department of Radiation Oncology, New York, NY, United States
7 Center for Advancement of Blood Cancer Therapies, New York, NY, United States, Department of Oncological Sciences, New York, NY, United States, Mount Sinai Tisch Cancer Center, New York, NY, United States
8 Section of MDS, Department of Leukemia, Houston, TX, United States
9 Section of MDS, Department of Leukemia, Houston, TX, United States
10 New York Genome Center, New York, NY, United States, Sandra and Edward Meyer Cancer Center, New York, NY, United States
11 New York Genome Center, New York, NY, United States, Sandra and Edward Meyer Cancer Center, New York, NY, United States
12 New York Genome Center, New York, NY, United States, Sandra and Edward Meyer Cancer Center, New York, NY, United States
13 New York Genome Center, New York, NY, United States, Sandra and Edward Meyer Cancer Center, New York, NY, United States

We are all somatic mosaics. As every person ages, they accumulate somatic mutations throughout the body. The blood system is particularly prone to acquiring mutations, seeding a patchwork of genetically distinct clones. Some of these mutations drive clonal expansion, termed clonal hematopoiesis of indeterminate potential (CHIP). CHIP increases with age and is linked to chronic low-grade inflammation, an increased risk of leukemia and cardiovascular disease, and poor outcomes in patients with solid tumors. Understanding the link between CHIP and these adverse outcomes requires defining how mutations alter cellular states.

Single-cell genotype-to-phenotype methods have provided striking insights into how individual mutations reshape cell behavior across disease contexts directly in human samples. But, applying these methods remains challenging. Clones are often rare, and genotyping efficiency is limited. Patient samples may also harbor clones with multiple co-occurring mutations that must be captured simultaneously. For example, TET2, the second most commonly mutated gene in CHIP, has challenged existing single-cell genotype-to-phenotype methods because it is lowly expressed and its mutations are scattered across the entire large gene rather than clustered at a few hotspots. 

To address these gaps, we developed GoTHaM, an ultra-high-throughput single-cell platform that captures genotype directly from genomic DNA alongside the full transcriptome, leveraging novel semipermeable capsule technology. GoTHaM uses combinatorial indexing to profile hundreds of thousands of cells per experiment at a fraction of the reagent cost of droplet-based platforms. Across multiple genomic loci, genotyping rates exceed 90% of cells with high accuracy, even when multiplexing multiple genotyping targets simultaneously. 

We applied GoTHaM to peripheral blood mononuclear cells (PBMCs) from individuals with known TET2 mutations. For the first time, we linked genotype to phenotype in rare clones with variant allele frequencies as low as 0.5%. We profiled 113,676 PBMCs from one individual harboring three distinct TET2 mutations, achieving genotyping efficiencies of 71%, 90%, and 98%, respectively. We find that different clones exhibit distinct lineage biases. Strikingly, we also observe one mutant clone enriched among cytotoxic natural killer cells (NKs) and another mutant clone enriched among a separate activated NK cluster. Two of the three clones are also enriched among pDCs, a cell type so rare that it is seldom captured by standard single-cell RNA sequencing, let alone resolved at the level of individual mutant clones. 

Together, these findings demonstrate that GoTHaM resolves the functional heterogeneity of CHIP at unprecedented resolution. GoTHaM distinguishes independent TET2-mutant clones that are significantly enriched in discrete cytotoxic or activated subclusters of NKs, highlighting clone-specific cell-state biases. We also identify significant enrichment of TET2-mutant cells in pDCs, a rare cell population poorly captured by other genotype-to-phenotype methods. These results reveal a previously hidden dimension of clonal architecture: the lineage- and state-specific distribution of mutant cells, which cannot be inferred from driver genotype or bulk variant allele frequency alone. This approach enables the comprehensive study of rare, small clones across CHIP, offering the first scalable strategy to decipher the mechanistic effects of TET2 and other CHIP driver mutations on the blood system. 

Joe Pelt, MSc, BSc: No relevant conflicts of interest to declare.